



Beth Rosenshein
Diamond Research Foundation
300 Center Drive, #248
Superior, Colorado 80027

Re: Docket No. FDA-2025-P-7111

Dear Ms. Rosenshein:

I am writing to inform you that the Food and Drug Administration (FDA) has not yet resolved the issues raised in your citizen petition received on December 16, 2025. Your petition requests that the “section, INDICATIONS and USAGE, of the Full Prescribing Information for Premarin tablets be updated to include pertinent information about the estrogen hormone, equilin.”

FDA has been unable to reach a decision on your petition because it raises complex issues requiring extensive review and analysis by Agency officials. This interim response is provided in accordance with FDA regulations on citizen petitions (21 CFR 10.30(e)(2)). We will respond to your petition as soon as we have reached a decision on your request.

Sincerely,

CAROL
BENNETT -S

Digitally signed by
CAROL BENNETT -S
Date: 2026.06.09
14:34:27 -04'00'

Carol J. Bennett
Deputy Director
Office of Regulatory Policy
Center for Drug Evaluation and Research